tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncowebtumors-282Research ArticleСтатьиГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК ПРОМЕЖУТОЧНОЙ СТАДИИ. BCLC B – ОФИЦИАЛЬНЫЕ РЕКОМЕНДАЦИИ, КАК СТРАТЕГИЯ БАЗИСНОГО ЛЕЧЕНИЯ И ТОЧКА ОТСЧЕТА В ОЦЕНКЕ ЭФФЕКТИВНОСТИ НОВЫХ ПОДХОДОВБредерВ. В.BrederV. V.

Бредер  Валерий Владимирович – кандидат медицинских наук, ведущий научный сотрудник отделения клинических биотехнологий, хирургическое отделение № 13 торако-абдоминального отдела

vbreder@yandex.ruЛактионовК. П.LaktionovK. P.

Лактионов Константин Павлович – доктор медицинских наук, профессор,  ведущий научный сотрудник отделения клинических биотехнологий, хирургическое отделение № 13 торако-абдоминального отдела

lkoskos@mail.ruНаучно-исследовательский институт клинической онкологии, Российский онкологический научный центр имени Н.Н. БлохинаRussian Federation20161711201604s12935Copyright © Бредер В.В., Лактионов К.П., 20162016Бредер В.В., Лактионов К.П.Breder V.V., Laktionov K.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/282

Представлен анализ Барселонской клинической классификации (BCLC) гепатоцеллюлярного рака (ГЦР). Подробно освещены лечебные рекомендации, предлагаемые BCLC для промежуточной стадии, рассмотрены современные мировые тенденции по внедрению эффективных  лечебных стратегий. Проведен анализ клинической гетерогенности промежуточной стадии (BCLC В), проблем диагностики и лечения. Подчеркнута важность стандартизованного алгоритма обследования для точной диагностики  промежуточной  стадии ГЦР. Рассмотрены перспективы оптимизации лечебных стратегий при BCLC В: поиск  и создание возможностей для радикального оперативного лечения, а также рациональное использование консервативных методов – химиоэмболизации и системной терапии – в лечении неоперабельных больных ГЦР.

гепатоцеллюлярный ракBCLCТАХЭцирроз печенисорафенибкатегория ALBIReferencesSiegel R. et al. Cancer statistics, 2014 // CA. Cancer J. Clin. 2014. Vol. 64, № 1. P. 9–29.Siegel R. et al. Cancer statistics, 2014 // CA. Cancer J. Clin. 2014. Vol. 64, № 1. P. 9–29.Ferlay J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN2012 // Int. J. Cancer. 2015. Vol. 136, № 5. P. E359–E386.Ferlay J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN2012 // Int. J. Cancer. 2015. Vol. 136, № 5. P. E359–E386.Bray F. et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008 // Int. J. Cancer. 2013. Vol. 132, № 5. P. 1133–1145.Bray F. et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008 // Int. J. Cancer. 2013. Vol. 132, № 5. P. 1133–1145.Greene F. L., Sobin L. H. The staging of cancer: a retrospective and prospective appraisal. // CA. Cancer J. Clin. Vol. 58, № 3. P. 180–190.Greene F. L., Sobin L. H. The staging of cancer: a retrospective and prospective appraisal. // CA. Cancer J. Clin. Vol. 58, № 3. P. 180–190.AJCC Cancer Staging Manual | Stephen Edge | Springer [Electronic resource]. URL: http://www.springer.com/us/book/9780387884400 (accessed: 22.03.2016).AJCC Cancer Staging Manual | Stephen Edge | Springer [Electronic resource]. URL: http://www.springer.com/us/book/9780387884400 (accessed: 22.03.2016).Pugh R. N. et al. Transection of the oesophagus for bleeding oesophageal varices. // Br. J. Surg. 1973. Vol. 60, № 8. P. 646–649.Pugh R. N. et al. Transection of the oesophagus for bleeding oesophageal varices. // Br. J. Surg. 1973. Vol. 60, № 8. P. 646–649.Llovet J. M., Br C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. // Semin. Liver Dis. 1999. Vol. 19, № 3. P. 329–338.Llovet J. M., Br C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. // Semin. Liver Dis. 1999. Vol. 19, № 3. P. 329–338.Llovet J. M., Burroughs A., Bruix J. Hepatocellular carcinoma. // Lancet (London, England). 2003. Vol. 362, № 9399. P. 1907–1917.Llovet J. M., Burroughs A., Bruix J. Hepatocellular carcinoma. // Lancet (London, England). 2003. Vol. 362, № 9399. P. 1907–1917.Llovet J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. // J. Natl. Cancer Inst. 2008. Vol. 100, № 10. P. 698–711.Llovet J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. // J. Natl. Cancer Inst. 2008. Vol. 100, № 10. P. 698–711.Bruix J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. // J. Hepatol. 2001. Vol. 35, № 3. P. 421–430.Bruix J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. // J. Hepatol. 2001. Vol. 35, № 3. P. 421–430.Forner A. et al. Hepatocellular carcinoma. // Lancet. Elsevier, 2012. Vol. 379, № 9822. P. 1245–1255.Forner A. et al. Hepatocellular carcinoma. // Lancet. Elsevier, 2012. Vol. 379, № 9822. P. 1245–1255.Kudo M. Review of 4th Single Topic Conference on HCC. Hepatocellular carcinoma: International consensus and controversies. // Hepatol. Res. 2007. Vol. 37 Suppl 2. P. S83–S87.Kudo M. Review of 4th Single Topic Conference on HCC. Hepatocellular carcinoma: International consensus and controversies. // Hepatol. Res. 2007. Vol. 37 Suppl 2. P. S83–S87.Tabrizian P., Roayaie S., Schwartz M. E. Current management of hepatocellular carcinoma. // World J. Gastroenterol. 2014. Vol. 20, № 30. P. 10223–10237.Tabrizian P., Roayaie S., Schwartz M. E. Current management of hepatocellular carcinoma. // World J. Gastroenterol. 2014. Vol. 20, № 30. P. 10223–10237.Livraghi T. et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? // Hepatology. 2008. Vol. 47, № 1. P. 82–89.Livraghi T. et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? // Hepatology. 2008. Vol. 47, № 1. P. 82–89.Llovet J. M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. // J. Hepatol. 2008. Vol. 48 Suppl 1. P. S20–S37.Llovet J. M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. // J. Hepatol. 2008. Vol. 48 Suppl 1. P. S20–S37.Arii S. et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. // Hepatology. 2000. Vol. 32, № 6. P. 1224–1229.Arii S. et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. // Hepatology. 2000. Vol. 32, № 6. P. 1224–1229.Sala M. et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. // Hepatology. 2004. Vol. 40, № 6. P. 1352–1360.Sala M. et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. // Hepatology. 2004. Vol. 40, № 6. P. 1352–1360.Cabibbo G. et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. // World J. Hepatol. 2012. Vol. 4, № 9. P. 256–261.Cabibbo G. et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. // World J. Hepatol. 2012. Vol. 4, № 9. P. 256–261.Lopez P. M., Villanueva A., Llovet J. M. Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. // Aliment. Pharmacol. Ther. 2006. Vol. 23, № 11. P. 1535–1547.Lopez P. M., Villanueva A., Llovet J. M. Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. // Aliment. Pharmacol. Ther. 2006. Vol. 23, № 11. P. 1535–1547.Llovet J. M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. // Hepatology. 2003. Vol. 37, № 2. P. 429–442.Llovet J. M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. // Hepatology. 2003. Vol. 37, № 2. P. 429–442.Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy // Crit. Rev. Oncol. Hematol. Elsevier Ireland Ltd, 2012. Vol. 83, № 2. P. 216–224.Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy // Crit. Rev. Oncol. Hematol. Elsevier Ireland Ltd, 2012. Vol. 83, № 2. P. 216–224.Takayasu K. et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. // Gastroenterology. 2006. Vol. 131, № 2. P. 461–469.Takayasu K. et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. // Gastroenterology. 2006. Vol. 131, № 2. P. 461–469.Burrel M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. // J. Hepatol. 2012. Vol. 56, № 6. P. 1330–1335.Burrel M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. // J. Hepatol. 2012. Vol. 56, № 6. P. 1330–1335.Llovet J. M. et al. Sorafenib in advanced hepatocellular carcinoma. // N. Engl. J. Med. 2008. Vol. 359, № 4. P. 378–390.Llovet J. M. et al. Sorafenib in advanced hepatocellular carcinoma. // N. Engl. J. Med. 2008. Vol. 359, № 4. P. 378–390.Llovet J. M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. // Hepatology. 1999. Vol. 30, № 6. P. 1434–1440.Llovet J. M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. // Hepatology. 1999. Vol. 30, № 6. P. 1434–1440.Llovet J. M. et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. // Hepatology. 1999. Vol. 29, № 1. P. 62–67.Llovet J. M. et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. // Hepatology. 1999. Vol. 29, № 1. P. 62–67.Yau T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. // Gastroenterology. Elsevier, Inc, 2014. Vol. 146, № 7. P. 1691–1700.e3.Yau T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. // Gastroenterology. Elsevier, Inc, 2014. Vol. 146, № 7. P. 1691–1700.e3.Giannini E. G. et al. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? 2013. Vol. 19, № 47. P. 8808–8821.Giannini E. G. et al. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? 2013. Vol. 19, № 47. P. 8808–8821.Bruix J., Sherman M. AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update // Hepatology. 2010. Vol. 42, № July. P. 1–35.Bruix J., Sherman M. AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update // Hepatology. 2010. Vol. 42, № July. P. 1–35.European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. // J. Hepatol. European Association for the Study of the Liver, 2012. Vol. 56, № 4. P. 908–943.European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. // J. Hepatol. European Association for the Study of the Liver, 2012. Vol. 56, № 4. P. 908–943.Bolondi L. et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions // Semin. Liver Dis. 2012. Vol. 32, № 4. P. 348–359.Bolondi L. et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions // Semin. Liver Dis. 2012. Vol. 32, № 4. P. 348–359.Leoni S. et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. // Dig. Liver Dis. Elsevier, 2014. Vol. 46, № 6. P. 549–555.Leoni S. et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. // Dig. Liver Dis. Elsevier, 2014. Vol. 46, № 6. P. 549–555.Piscaglia F., Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded? // Dig. Liver Dis. Elsevier, 2010. Vol. 42 Suppl 3. P. S258–S263.Piscaglia F., Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded? // Dig. Liver Dis. Elsevier, 2010. Vol. 42 Suppl 3. P. S258–S263.Cucchetti A. et al. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma // Hepatology. 2015. Vol. 61, № 3. P. 905–914.Cucchetti A. et al. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma // Hepatology. 2015. Vol. 61, № 3. P. 905–914.Ha Y. et al. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. // J. Gastroenterol. Hepatol. 2014. Vol. 29, № 4. P. 787–793.Ha Y. et al. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. // J. Gastroenterol. Hepatol. 2014. Vol. 29, № 4. P. 787–793.Wang J.– H. et al. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. // J. Gastroenterol. Hepatol. 2015. Vol. 30, № 2. P. 358–363.Wang J.– H. et al. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. // J. Gastroenterol. Hepatol. 2015. Vol. 30, № 2. P. 358–363.Weinmann A. et al. Survival analysis of proposed BCLC B subgroups in hepatocellular carcinoma patients. // Liver Int. 2014. № 3. P. 1–10.Weinmann A. et al. Survival analysis of proposed BCLC B subgroups in hepatocellular carcinoma patients. // Liver Int. 2014. № 3. P. 1–10.Yamakado K., Hirota S. Sub-classification of intermediate- stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas // World J. Gastroenterol. 2015. Vol. 21, № 37. P. 10604–10608.Yamakado K., Hirota S. Sub-classification of intermediate- stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas // World J. Gastroenterol. 2015. Vol. 21, № 37. P. 10604–10608.Choi S. H. et al. Diagnostic criteria for hepatocellular carcinoma <3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. // J. Hepatol. Elsevier, 2016. Vol. 64, № 5. P. 1099–1107.Choi S. H. et al. Diagnostic criteria for hepatocellular carcinoma <3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. // J. Hepatol. Elsevier, 2016. Vol. 64, № 5. P. 1099–1107.Sun P. et al. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis // PLoS One. 2014. Vol. 9, № 7.Sun P. et al. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis // PLoS One. 2014. Vol. 9, № 7.Zhou Z.– G. et al. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. // Chin. J. Cancer.???, 2015. Vol. 34, № 1. P. 14.Zhou Z.– G. et al. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. // Chin. J. Cancer.???, 2015. Vol. 34, № 1. P. 14.Kadalayil L. et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer // Ann. Oncol. 2013. Vol. 24, № 10. P. 2565–2570.Kadalayil L. et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer // Ann. Oncol. 2013. Vol. 24, № 10. P. 2565–2570.Adhoute X. et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments // World J. Hepatol. 2016. Vol. 8, № 17. P. 703.Adhoute X. et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments // World J. Hepatol. 2016. Vol. 8, № 17. P. 703.Arizumi T. et al. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma // Liver Cancer TACE Refract. HCC Liver Cancer. 2015. Vol. 44. P. 253–262.Arizumi T. et al. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma // Liver Cancer TACE Refract. HCC Liver Cancer. 2015. Vol. 44. P. 253–262.Ogasawara S. et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization // Oncol. 2014. Vol. 87, № 6. P. 330–341.Ogasawara S. et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization // Oncol. 2014. Vol. 87, № 6. P. 330–341.Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M E.A. STORM: A phase III randomized, double-blind, placebo- controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). // J Clin Oncol. 2014. Vol. 32, № suppl 4. P. abstr 4006.Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M E.A. STORM: A phase III randomized, double-blind, placebo- controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). // J Clin Oncol. 2014. Vol. 32, № suppl 4. P. abstr 4006.Lencioni R. et al. Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate-Stage HCC: Phase II, Randomized, Double-Blind SPACE Trial // J. Hepatol. 2016. P. 44.Lencioni R. et al. Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate-Stage HCC: Phase II, Randomized, Double-Blind SPACE Trial // J. Hepatol. 2016. P. 44.Pawlik T. M. et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma // J. Clin. Oncol. 2011. Vol. 29, № 30. P. 3960–3967.Pawlik T. M. et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma // J. Clin. Oncol. 2011. Vol. 29, № 30. P. 3960–3967.Kudo M. et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma // Eur. J. Cancer. Elsevier Ltd, 2011. Vol. 47, № 14. P. 2117–2127.Kudo M. et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma // Eur. J. Cancer. Elsevier Ltd, 2011. Vol. 47, № 14. P. 2117–2127.Llovet J. J.M. et al. Sorafenib in advanced hepatocellular carcinoma. // N. Engl. J. Med. 2008. Vol. 359, № 4. P. 378–390.Llovet J. J.M. et al. Sorafenib in advanced hepatocellular carcinoma. // N. Engl. J. Med. 2008. Vol. 359, № 4. P. 378–390.Cheng A.– L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. // Lancet. Oncol. Elsevier, 2009. Vol. 10, № 1. P. 25–34.Cheng A.– L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. // Lancet. Oncol. Elsevier, 2009. Vol. 10, № 1. P. 25–34.Bruix J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. // J. Hepatol. European Association for the Study of the Liver, 2012. Vol. 57, № 4. P. 821–829.Bruix J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. // J. Hepatol. European Association for the Study of the Liver, 2012. Vol. 57, № 4. P. 821–829.Raoul J. L. et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization // Cancer Treat. Rev. Elsevier Ltd, 2011. Vol. 37, № 3. P. 212–220.Raoul J. L. et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization // Cancer Treat. Rev. Elsevier Ltd, 2011. Vol. 37, № 3. P. 212–220.Lencioni R. et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): Second interim analysis // Int. J. Clin. Pract. 2014. Vol. 68, № 5. P. 609–617.Lencioni R. et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): Second interim analysis // Int. J. Clin. Pract. 2014. Vol. 68, № 5. P. 609–617.Iavarone M. et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. // Hepatology. 2011. Vol. 54, № 6. P. 2055–2063.Iavarone M. et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. // Hepatology. 2011. Vol. 54, № 6. P. 2055–2063.Johnson P. J. и др. An assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach – The ALBI grade // J. Clin. Oncol. 2015. Т. 33, № 6. С. 550–558.Johnson P. J. и др. An assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach – The ALBI grade // J. Clin. Oncol. 2015. Т. 33, № 6. С. 550–558.Бредер В. В., и др. Факторы прогноза выживаемости больных гепатоцеллюлярным раком в российской популяции пациентов. Опыт Российского онкологического научного центра им.Н.Н.Блохина.// Вестник ФГБУ» РОНЦ им. Н. Н. Блохина», т. 27, № 2–2016, стр 75–82.Бредер В. В., и др. Факторы прогноза выживаемости больных гепатоцеллюлярным раком в российской популяции пациентов. Опыт Российского онкологического научного центра им.Н.Н.Блохина.// Вестник ФГБУ» РОНЦ им. Н. Н. Блохина», т. 27, № 2–2016, стр 75–82.

The authors declare that there are no conflicts of interest present.